4DMT's Ixo-vec Gene Therapy for nAMD Shows Progress in LUNA Phase 2 Trial

The article discusses the clinical progress of the LUNA Phase 2 trial for Ixo-vec gene therapy in treating nAMD. The trial has shown promising results, with 71% of patients achieving a 12-week stable or improved visual acuity, and 47% achieving a 24-week stable or improved visual acuity. The study has also shown a favorable safety profile, with only mild or moderate ocular and systemic adverse events. The author highlights the potential of Ixo-vec gene therapy to provide a long-term treatment option for patients with nAMD.